Filing Summary
Business Context and Reporting Period
Xeris Biopharma Holdings, Inc. filed this Form 8-K on August 8, 2023, under Items 2.02 and 9.01. The filing announces the release of business highlights and results of operations for the three and six months ended June 30, 2023. The referenced second-quarter 2023 press release is furnished as Exhibit 99.1, but its substantive contents are not included in the provided filing text.
Financial and Operating Metrics
- The filing text does not provide clear values for revenue, profit or loss, cash flow, margins, debt, liquidity, cash balance, or other financial metrics.
- The filing text does not provide the underlying business highlights or operating results referenced in Exhibit 99.1.
Material Changes Versus Prior Comparable Period
The filing text does not provide a comparison with the prior-year or prior-period results. Any material changes would need to be verified in the furnished press release or the company’s subsequent financial disclosures.
Guidance, Outlook, Risks, and Unusual Items
- No guidance, outlook, management commentary, risk update, contingency, or unusual item is described in the provided text.
- The filing is primarily a notification that the company issued its second-quarter 2023 results press release.
- Item 2.02 information, including Exhibit 99.1, is furnished rather than filed for purposes of Section 18 of the Exchange Act and is not incorporated by reference except where expressly stated.
Investor Verification Checklist
- Obtain and review Exhibit 99.1 for second-quarter and six-month 2023 revenue, earnings, cash flow, liquidity, debt, and operating metrics.
- Verify year-over-year and sequential changes against the company’s Form 10-Q for the quarter ended June 30, 2023.
- Check for management guidance, updated outlook, non-GAAP reconciliations, and liquidity commentary in the press release.
- Review subsequent filings for any financing, covenant, clinical, commercial, or regulatory developments.